Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04588025 · ClinicalTrials.gov registry record · NA

Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response

A NA study of Pancreatic Cancer, sponsored by Ohio State University.

Recruiting
Registry status
NA
Development phase
55
Enrollment target
2
Study locations

NCT04588025: Recruiting NA study of Pancreatic Cancer, sponsored by Ohio State University.

NCT04588025 is a NA study of Pancreatic Cancer that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 55 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04588025, a NA study of Pancreatic Cancer, is actively recruiting participants, sponsored by Ohio State University.

RECRUITING
Registry status
NA
Development phase
55 participants
Enrollment target
2
Study locations

Study Summary

The goal of this study is to investigate whether the therapeutic response of pancreatic tumors can be accurately assessed using quantitative DCE-MRI, when the inter/intra-scanner variability is reduced using the Point-of-care Portable Perfusion Phantom, P4. The intra-scanner variability over time leads to errors in therapy monitoring, while the inter-scanner variability impedes the comparison of data among institutes. The P4 is small enough to be imaged concurrently in the bore of a standard MRI scanner with a patient for real-time quality assurance. The P4 is safe, inexpensive and easily operable, thus it has great potential for widespread and routine clinical use for accurate diagnosis, prognosis and therapy monitoring. This study has identified two arms, one arm is healthy individuals that will undergo DCE MRI at three different MRI locations to establish baseline results. The healthy volunteers will undergo these MRIs prior to the second arm, which contains patients with pancreatic cancer. The pancreatic cancer patients will only have DCE MRI done at one location.

Primary Outcome

This outcome is assigned to the 5 healthy volunteers that we will be evaluated on 3 different MRIs. Two scans will be done to establish baseline measures.

Conditions Studied

Interventions

  • DEVICE Point-of-care Portable Perfusion Phantom, P4

Study Locations (2)

Ohio

  • The Ohio State University - Columbus

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2020-10-14
Est. Completion 2027-10
Phase NA
Ohio State University

552 total trials

What NCT04588025 shows while recruiting

NCT04588025 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Point-of-care Portable Perfusion Phantom, P4 is the first listed.

NCT04588025 reports a single indexed study location in Ohio, Tennessee.

Frequently Asked Questions

What is clinical trial NCT04588025 about?

NCT04588025 is a clinical study titled "Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response". The goal of this study is to investigate whether the therapeutic response of pancreatic tumors can be accurately assessed using quantitative DCE-MRI, when the inter/intra-scanner variability is reduced using the Point-of-care Portable Perfusion Phantom, P4. The intra-scanner variability over time le...

What is the current status of trial NCT04588025?

This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2020-10-14. Estimated completion is 2027-10.

What conditions does trial NCT04588025 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT04588025?

The interventions under investigation include: Point-of-care Portable Perfusion Phantom, P4 (DEVICE).

Who is sponsoring clinical trial NCT04588025?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04588025 being conducted?

This trial has 2 study locations across Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04588025's enrollment target sits among peer trials

55 146th of 278 higher than 132 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04588025, the US trial registry maintained by the National Library of Medicine. NCT04588025 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.